Skip to main content
Log in

Anti-obesity drug AEs more common with phentermine and liraglutide

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Choi YJ, et al. A 10-Year Nationwide Pharmacovigilance Assessment on Anti-Obesity Medications and Factors Associated with Serious Adverse Events FASEB Journal : 17 May 2022. Available from: URL: https://doi.org/10.1096/fasebj.2022.36.S1.R3296

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anti-obesity drug AEs more common with phentermine and liraglutide. Reactions Weekly 1907, 5 (2022). https://doi.org/10.1007/s40278-022-15264-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-15264-1

Navigation